Benefits
Metabolic syndrome marker support
A 12-week randomized controlled trial of the Crominex 3+-style chromium + Phyllanthus emblica + shilajit complex in adults with metabolic syndrome risk factors reported improvements in pulse wave velocity, flow-mediated dilation, insulin sensitivity markers, and lipid profile, particularly at the higher-dose arm.
Endothelial function support
The amla (Capros®) component supports endothelial function and reduces oxidative stress in cardiometabolic populations, contributing to the formula's vascular-tone benefits as observed in the combined human trial.
Healthy lipid profile
The amla component of the complex consistently reduces calculated LDL cholesterol, total cholesterol/HDL ratio, and hsCRP in overweight adults and people with metabolic syndrome, supporting the lipid endpoints reported in the combined Crominex-style trial.
Insulin sensitivity support
Chromium contributes to normal macronutrient metabolism and supports insulin receptor signaling, while the amla polyphenol component independently supports glycemic markers — together backing the insulin-sensitivity gains seen in the combined trial.
Mechanism of action
Chromium and insulin receptor signaling
Chromium is a cofactor for chromodulin (low-molecular-weight chromium-binding substance), which amplifies insulin receptor tyrosine kinase activity and supports normal glucose uptake in insulin-responsive tissues.
Amla galloyl-tannin antioxidant defense
Emblicanin A and B and gallic acid from the Capros® amla component quench reactive oxygen species, reduce LDL oxidation, and preserve endothelial nitric oxide bioavailability, contributing to the vascular endpoints observed in the combined trial.
Shilajit mineral and electron-transport support
Purified shilajit (PrimaVie®) provides fulvic acid and dibenzo-α-pyrones that act as mineral carriers and may support mitochondrial electron-transport efficiency, complementing the chromium and amla components in the proprietary blend.
Endothelial NO and inflammation modulation
The combined amla + shilajit polyphenol load reduces NF-κB-driven inflammation and supports nitric oxide-dependent vasodilation, helping explain the improvements in flow-mediated dilation and pulse wave velocity observed in the Crominex-style RCT.
Clinical trials
12-week randomized, double-blind, placebo-controlled trial in 166 sedentary adults (≥2 metabolic syndrome risk factors, mean BMI ~34) testing the Crominex-style complex at 400 μg chromium + 6 mg P. emblica + 6 mg shilajit and 800 μg chromium + 12 mg P. emblica + 12 mg shilajit versus P. emblica-only arms and placebo. Endpoints: pulse wave velocity, flow-mediated dilation, platelet aggregation, insulin sensitivity, lipid profile, body composition.
166 sedentary adults with metabolic syndrome risk factors (109 completers). 12 weeks.
Greater benefits were observed with the higher-dose Crominex-style arm and the higher-dose P. emblica arm, with improvements in pulse wave velocity, flow-mediated dilation, platelet aggregation, insulin sensitivity markers, and lipid profile — most pronounced around 6 weeks. The combined formula performed favorably against the comparators.
Randomized, double-blind, controlled trial in 80 adults with type 2 diabetes; standardized P. emblica extract (250 or 500 mg twice daily) versus atorvastatin 10 mg and placebo over 12 weeks. Endpoints: endothelial function (reflection index), malondialdehyde, glutathione, hsCRP, lipid profile, HbA1c.
80 adults with type 2 diabetes. 12 weeks.
All active groups significantly improved endothelial reflection index versus placebo, with the 500 mg twice-daily amla arm producing reductions in malondialdehyde and hsCRP comparable to atorvastatin 10 mg. Lipid profile and HbA1c also improved. Supports the amla component of the Crominex blend.
Double-blind randomized clinical trial in 56 adults with type 2 diabetes testing 50 μg or 200 μg chromium nicotinate versus placebo for 90 days. Endpoints: HOMA-IR, HOMA-β, glucose, lipid profile, body composition.
56 adults with type 2 diabetes. 90 days.
Neither 50 μg nor 200 μg chromium nicotinate produced clinically significant improvements in glucose homeostasis or anthropometry versus placebo. A modest weight reduction (~1 kg) was seen in the lower-dose group. Illustrates why the Crominex formulation combines chromium with amla and shilajit rather than relying on chromium alone.